Skip to main content
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

Download the PDF
CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Back to Top
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS
Download the PDF

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

‍

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

‍

Study Design

  • Hybrid
  • BYOD ePRO
  • Site Training
  • eClinRo
  • eConsent
  • 10 Site Partners
  • CRO Partner

‍

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).

Discover More Case Studies

Discover More News

Discover More White Papers

Discover More Blogs

Discover More Playbooks

Discover More Webinars

Discover More Events

CNS

Sub-Clinical Mood Disorders

A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.

› Read More
CNS

ADHD Study

A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.

› Read More